BACKGROUND: Hearing impairment is a prevalent clinical feature in Morquio syndrome (mucopolysaccharidosis IVA or MPS IVA) patients, often presenting in diverse forms: conductive, sensorineural, or a combination known as mixed hearing loss. The mixed form entails a blend of both conductive and sensorineural elements, typically exhibiting a progressive trajectory. This scoping review aimed to comprehensively analyze available evidence pertaining to the pathophysiology, classification, epidemiology, and clinical management of hearing loss in individuals with MPS IVA. METHODS: Targeted literature was searched using MEDLINE, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Web of Science, the Cochrane Library, Trip Medical Database, Embase, ScienceDirect, and Google Scholar, with a second search cycle to identify gray literature. A systematic search strategy using Medical Subject Headings keywords was implemented: "Hearing Disorders" OR "Hearing Loss" AND "Mucopolysaccharidosis IV" or "Hearing Disorders" OR "Hearing Loss" AND "Mucopolysaccharidosis IV." The identified bibliography was uploaded to COVIDENCE platform for information management. Articles were screened by 3 independent reviewers following the eligibility criteria. RESULTS: Twenty-seven articles met the inclusion criteria, spanning information from 568 patients across 16 different countries. None of the studies had complete epidemiological information. Only 2 studies provided sufficient data to address the pathophysiology, while 3 addressed management and treatment. Hearing loss was reported in 210 of 568 patients. A total of 19.2% of patients reported recurrent ear infections. None of the studies reported vertigo, tinnitus, or dizziness in the patients. Pure-tone audiometry was the primary test used to diagnose and monitor auditory impairment in patients with Morquio syndrome. CONCLUSIONS: Five hundred sixty-eight patients with MPS IVA were identified, of whom 210 (37%) developed hearing loss, the most common of which was moderate. Despite the lack of information on the diagnosis and management of hearing loss in Morquio syndrome, this study found that approximately one-third of participants exhibited some form of auditory impairment, with the majority of these cases being sensorineural in nature.

Centro de Investigaciones Clínicas Fundación Valle del Lili Cali Colombia

Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras Universidad Iccesi Cali Colombia

Departamento de Ciencias Básicas Médicas Facultad de Salud Universidad Icesi Cali Colombia

Department of ENT University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Pediatrics and Inherited Metabolic Disorders General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Pediatrics Thomayer's University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Genetic Division Fundación Valle del Lili Cali Colombia

Hospital Universitario del Valle Cali Colombia

School of Basic Sciences Universidad del Valle Cali Colombia

Zobrazit více v PubMed

Gomez AM, García-Robles R, Fernando Suárez-Obando F. Estimación de las frecuencias de las mucopolisacaridosis y análisis de agrupamiento espacial en los departamentos de Cundinamarca y Boyacá. Biomedica. 2012;32:617–22. PubMed

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54. PubMed

Hendriksz CJ, Burton B, Fleming TR, et al. ; STRIVE Investigators. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37:979–90. PubMed PMC

Nagao K, Morlet T, Haley E, et al. . Neurophysiology of hearing in patients with mucopolysaccharidosis type IV. Mol Genet Metab. 2018;123:472–8. PubMed PMC

Diaz-Ordoñez L, Candelo E, Silva-Cuero K, et al. . Hearing loss in patients with Morquio syndrome: protocol for a scoping review. JMIR Res Protoc. 2022;11:e32986. PubMed PMC

Chapter 11: Scoping reviews. In: JBI Manual for Evidence Synthesis. JBI; 2020.

Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.

Levac D, Colquhoun H, O’brien KK. Scoping studies: advancing the methodology. 2010;5:69. PubMed PMC

Papsin BC, Vellodi A, Bailey M, Ratcliffe PC. Otologic and laryngologic manifestations of mucopolysaccharidoses after bone marrow transplantation. Otolaryngol Head Neck Surg. 1998;118:31–6. PubMed

Lee CL, Lee KS, Chuang CK, et al. . Otorhinolaryngological management in Taiwanese patients with mucopolysaccharidoses. Int J Med Sci. 2021;2021:3373–9. PubMed PMC

Lin HY, Chuang CK, Chen MR, et al. . Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. 2014;9:21. PubMed PMC

Leong HY, Abdul Azize NA, Chew HB, et al. . Clinical, biochemical and genetic profiles of patients with mucopolysaccharidosis type IVA (Morquio A syndrome) in Malaysia: the first national natural history cohort study. Orphanet J Rare Dis. 2019;14:143. PubMed PMC

Lee NH, Cho SY, Maeng SH, et al. . Clinical, radiologic, and genetic features of Korean patients with mucopolysaccharidosis IVA. Korean J Pediatr. 2012;55:430–7. PubMed PMC

Montã AM, Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165–74. PubMed

Borlot F, Arantes PR, Quaio CR, et al. . Mucopolysaccharidosis type IVA: evidence of primary and secondary central nervous system involvement. Am J Med Genet A. 164:1162–9. PubMed

Ahn J, Lee J, Park YI, et al. . Auditory characteristics in patients with mucopolysaccharidosis. 2019. PubMed

Politei J, Porras-Hurtado GL, Guelbert N, Fainboim A, Dain D, et al. . Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes Funding information BioMarin Brasil Farmaceutica LTDA. 2020. PubMed PMC

Vargas-Gamarra MF, de Paula-Vernetta C, Vitoria Miñana I, Ibañez-Alcañiz I, Cavallé-Garrido L, Alamar-Velazquez A. Hallazgos audiológicos en niños con mucopolisacaridosis tipos i-iv. Acta Otorrinolaringol Esp. 2017;68:262–8. PubMed

Hirst L, Mubeen S, Abou-Ameira G, Chakrapani A. Mucopolysaccharidosis (MPS): Review of the literature and case series of five pediatric dental patients. Clin Case Rep. 2021;9:1704–10. PubMed PMC

Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharide storage disorders; 130:233. PubMed

Riedner ED, Stefan Levin L. Hearing Patterns in Morquio’s Syndrome (Mucopolysaccharidosis IV). Arch Otolaryngol. 1977;103:518–520. PubMed

Chaves AG, Tavares KB, Val JR, Matsuyama C, Riskalla PE. Morquio’s syndrome: case report and review. Rev Bras Otorrinolaringol. 2003;69:267–71.

Santos S, López L, González L, Jesús Domínguez M. Hearing loss and airway problems in children with mucopolysaccharidoses. Acta Otorrinolaringol Esp. 2011;62:411–7. PubMed

Kumar P, Harit P, Sharma R. Audiological outcomes in cases with mucopolysaccharidoses (Morquio’s disease). Indian J Otol. 2014;20:75–8.

Gökdoğan C, Altinyay S, Gökdoğan O, et al. . Audiologic evaluations of children with mucopolysaccharidosis. Braz J Otorhinolaryngol. 2016;82:281–4. PubMed PMC

Hiramatsu M, Nakamura K. Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome (case report). Mol Genet Metab Rep. 2017;13:76–9. PubMed PMC

Nagao K, Walter C, Parkes WJ, et al. . Cochlear implantation in a patient with mucopolysaccharidosis IVA. SAGE Open Med Case Rep. 2019;7:2050313X1987379. PubMed PMC

Murgasova L, Jurovcik M, Jesina P, et al. . Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol. 2020;135:110137. PubMed

Canda E, Yazici H, Er E, Eraslan C, Kalkan Uçar S, Çoker M. Clinical presentation and follow up of patients with mucopolysaccharidosis type IVA (Morquio A Disease): single center experience. J Pediatr Res. 2018:28–33.

Kilavuz S, Basaran S, Kor D, et al. . Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series. Orphanet J Rare Dis. 2021;16:144. PubMed PMC

Quijada-Fraile P, Arranz Canales E, Martín-Hernández E, et al. . Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience. Orphanet J Rare Dis. 2021;16:464. PubMed PMC

Nakamura-Utsunomiya A, Nakamae T, Kagawa R, et al. . A case report of a Japanese boy with Morquio A syndrome: effects of enzyme replacement therapy initiated at the age of 24 months. Int J Mol Sci. 2020;2020:989. PubMed PMC

Y. Ito TTYETN. Hearing Defect in Morquio’s Syndrome. J-STAGE. 1982. Jun 25 [cited April 8, 2024]; Available at: https://www.jstage.jst.go.jp/article/orltokyo1958/25/6/25_6_615/_pdf. Accessed XXX.

Xu L, Ren Y, Yin J, et al. . Analysis of endocrine hormone metabolism level in a Chinese patient with mucopolysaccharidosis IVA: a case report. Medicine (Baltimore). 2018;97:e12393. PubMed PMC

Sawamoto K, Álvarez González JV, Piechnik M, et al. . Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21:1517. PubMed PMC

Solano VM, Mandujano CYC, Avila-Rejon CA, Espin VH, Montaño HPQ. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries. Mol Genet Metab Rep. 2021;28:100769. PubMed PMC

Zanetti A, D’Avanzo F, AlSayed M, et al. . Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): a review and classification of GALNS gene variants and reporting of 68 novel variants. Hum Mutat. 2021;42:1384–98. PubMed PMC

Wolfberg J, Chintalapati K, Tomatsu S, Nagao K. Hearing loss in mucopolysaccharidoses: current knowledge and future directions. Diagnostics (Basel). 2020;10:554. PubMed PMC

Bianchi PM, Gaini R, Vitale S. ENT and mucopolysaccharidoses. Ital J Pediatr. 2018;44(Suppl 2):127. PubMed PMC

Giraldo LJM, Arturo-Terranova D, Soto JMS. Otorhinolaryngological findings in patients from Southwestern Colombia with clinical, enzymatic and molecular diagnosis of mucopolysaccharidosis II, IV-A and VI. J Inborn Errors Metab Screen. 2020;8.